ZA200810053B - Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same - Google Patents

Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same

Info

Publication number
ZA200810053B
ZA200810053B ZA200810053A ZA200810053A ZA200810053B ZA 200810053 B ZA200810053 B ZA 200810053B ZA 200810053 A ZA200810053 A ZA 200810053A ZA 200810053 A ZA200810053 A ZA 200810053A ZA 200810053 B ZA200810053 B ZA 200810053B
Authority
ZA
South Africa
Prior art keywords
valsartan
hydrochlorothiazide
amlodipine
making
same
Prior art date
Application number
ZA200810053A
Other languages
English (en)
Inventor
Cao Yu
Joshi Yatindra
Li Ping
Pudipeddi Madhusudhan
Royce Alan Edward
Wagner Robert Frank
Zhu Jiahao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38662673&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200810053(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200810053B publication Critical patent/ZA200810053B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA200810053A 2006-06-27 2008-11-26 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same ZA200810053B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US80588306P 2006-06-27 2006-06-27

Publications (1)

Publication Number Publication Date
ZA200810053B true ZA200810053B (en) 2009-11-25

Family

ID=38662673

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200810053A ZA200810053B (en) 2006-06-27 2008-11-26 Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same

Country Status (22)

Country Link
US (2) US20100003321A1 (enExample)
EP (1) EP2037893A2 (enExample)
JP (1) JP2009542709A (enExample)
KR (1) KR20090021191A (enExample)
CN (2) CN101478956B (enExample)
AR (1) AR061627A1 (enExample)
AU (1) AU2007265138A1 (enExample)
BR (1) BRPI0713785A2 (enExample)
CA (1) CA2654986A1 (enExample)
CL (1) CL2007001870A1 (enExample)
EC (1) ECSP088987A (enExample)
IL (1) IL195797A0 (enExample)
MA (1) MA30529B1 (enExample)
MX (1) MX2008016532A (enExample)
NO (1) NO20090314L (enExample)
NZ (1) NZ573295A (enExample)
PE (2) PE20080991A1 (enExample)
RU (1) RU2449786C2 (enExample)
TN (1) TNSN08538A1 (enExample)
TW (1) TW200808379A (enExample)
WO (1) WO2008002905A2 (enExample)
ZA (1) ZA200810053B (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3239B1 (ar) 2008-09-22 2018-03-08 Novartis Ag تركيبات جالينية من مركبات عضوية
US20120107397A1 (en) * 2009-07-03 2012-05-03 Hetero Research Foundation Pharmaceutical compositions of valsartan
CA2775962C (en) 2009-09-30 2017-09-05 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives
US10610489B2 (en) * 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
CN102091069A (zh) * 2009-12-11 2011-06-15 浙江华海药业股份有限公司 缬沙坦和氨氯地平的复方制剂及其制备方法
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
CN101829111B (zh) * 2010-05-23 2014-12-17 浙江华海药业股份有限公司 含有缬沙坦的固体制剂及其制备方法
CN102716132B (zh) * 2011-03-29 2015-09-30 石药集团中奇制药技术（石家庄）有限公司 复方氨氯地平/缬沙坦/氢氯噻嗪片及其制备方法
EP2797580A2 (en) * 2011-12-26 2014-11-05 Novartis AG Tablets and dry-coated agents
US9192617B2 (en) 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN102614190A (zh) * 2012-04-17 2012-08-01 北京哈三联科技股份有限公司 含有缬沙坦、氨氯地平和氢氯噻嗪的片剂及其制备方法
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
MX358211B (es) 2012-07-23 2018-08-10 Landsteiner Scient S A De C V Una composición farmacéutica de liberación comprendiendo hidroclorotiazida, losartán y basilato de amlodipino.
CN103655580B (zh) * 2012-08-28 2017-12-01 海南中济医药科技有限公司 一种含有缬沙坦、苯磺酸氨氯地平和氢氯噻嗪的药物组合物及其制备方法
WO2014058047A1 (ja) * 2012-10-12 2014-04-17 味の素株式会社 カルシウム拮抗薬／アンジオテンシンｉｉ受容体拮抗薬含有医薬製剤の製造方法
CN102846625A (zh) * 2012-10-18 2013-01-02 海口华仕联医药科技有限公司 一种稳定的缬沙坦、氨氯地平和氢氯噻嗪的药物组合及其制备方法
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2702174T3 (es) 2013-04-05 2019-02-27 Boehringer Ingelheim Int Usos terapéuticos de empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
JP2016520564A (ja) 2013-04-18 2016-07-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 医薬組成物、治療方法及びその使用
CZ2013783A3 (cs) 2013-10-08 2015-04-15 Zentiva, K. S Stabilní farmaceutická kompozice obsahující amlodipin a valsartan
CN105106962A (zh) * 2015-08-29 2015-12-02 西安力邦肇新生物科技有限公司 一种复方降压制剂及其应用
US20200316029A1 (en) * 2016-05-30 2020-10-08 Boehringer Ingelheim International Gmbh Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
MX2019005435A (es) 2016-11-10 2019-07-10 Boehringer Ingelheim Int Composicion farmaceutica, metodos para tratamiento y sus usos.
AU2017400276B2 (en) 2017-02-27 2024-01-11 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
ES3035734T3 (en) 2017-11-30 2025-09-08 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
WO2022132067A1 (en) * 2020-12-18 2022-06-23 Santa Farma Ilac Sanayii A.S. Stable bilayer tablet compositions
CN113171352A (zh) * 2021-04-15 2021-07-27 海南锦瑞制药有限公司 一种沙坦类降压复方制剂的制备方法
GR1010320B (el) * 2021-08-04 2022-10-11 Win Medica Φαρμακευτικη Ανωνυμη Εταιρεια, Στερεες φαρμακοτεχνικες μορφες ιρβεσαρτανης, υδροχλωροθειαζιδης και αμλοδιπινης

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057344A (en) * 1991-11-26 2000-05-02 Sepracor, Inc. Methods for treating hypertension, and angina using optically pure (-) amlodipine
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin
RU2188636C2 (ru) * 1998-03-26 2002-09-10 Др. Редди'С Лабораторис Лтд. Стабильный фармацевтический препарат, содержащий амлодипина безилат и атенолол
AU2002226365A1 (en) * 2000-12-01 2002-06-11 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
ES2445041T3 (es) * 2002-01-16 2014-02-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Método para la preparación de telmisartán amorfo
US6869970B2 (en) 2002-02-04 2005-03-22 Novartis Ag Crystalline salt forms of valsartan
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
KR100580168B1 (ko) 2003-03-21 2006-05-16 삼성전자주식회사 다중 홈 에이전트 제어장치 및 방법
WO2005070463A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine malate and an angiotensin receptor blocker and methods of their use
AU2005245027B2 (en) 2004-05-21 2011-05-19 Accu-Break Technologies, Inc. Pharmaceutical tablets having a separation mark positioned on the side of said tablets
EP1814527B2 (en) * 2004-11-05 2020-11-18 Boehringer Ingelheim International GmbH Bilayer tablet comprising telmisartan and amlodipine
CN100389830C (zh) * 2005-05-08 2008-05-28 广州市施柏医药科技有限公司 一种治疗高血压的药物组合物

Also Published As

Publication number Publication date
CL2007001870A1 (es) 2008-06-13
ECSP088987A (es) 2009-01-30
KR20090021191A (ko) 2009-02-27
WO2008002905A3 (en) 2008-12-11
US8475839B2 (en) 2013-07-02
NZ573295A (en) 2012-01-12
CA2654986A1 (en) 2008-01-03
WO2008002905A2 (en) 2008-01-03
PE20120542A1 (es) 2012-05-14
PE20080991A1 (es) 2008-09-05
AR061627A1 (es) 2008-09-10
IL195797A0 (en) 2009-09-01
AU2007265138A1 (en) 2008-01-03
HK1133818A1 (en) 2010-04-09
EP2037893A2 (en) 2009-03-25
CN101478956A (zh) 2009-07-08
NO20090314L (no) 2009-01-26
JP2009542709A (ja) 2009-12-03
CN101478956B (zh) 2013-03-20
RU2009102273A (ru) 2010-08-10
RU2449786C2 (ru) 2012-05-10
MA30529B1 (fr) 2009-06-01
TW200808379A (en) 2008-02-16
TNSN08538A1 (en) 2010-04-14
US20120164218A1 (en) 2012-06-28
BRPI0713785A2 (pt) 2012-10-30
US20100003321A1 (en) 2010-01-07
MX2008016532A (es) 2009-01-19
CN103169711A (zh) 2013-06-26

Similar Documents

Publication Publication Date Title
ZA200810053B (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
IL189021A0 (en) Solid dosage forms of valsartan and amlodipine and method of making the same
HRP20190408T1 (hr) Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
GB2454620B (en) Solid dosage form of olmesartan medoxomil and amlodipine
GB0718972D0 (en) Compounds and methods of making the compounds
EP2008628A4 (en) PACKING WITH AN ARTICLE AND METHOD OF MANUFACTURING THEREOF
ZA200910116B (en) Pharmaceutical composition comprising amlodipine and losartan
ZA200810460B (en) Modified beta-lactamase and method for its preparation
EP1993322A4 (en) ULTRASOUND SENSOR, AND METHOD OF MANUFACTURING SAME
ZA200806922B (en) Delay elements, detonators containing the same and methods of making
ZA201005442B (en) Pharmaceutical compositions of amlodipine and valsartan
PT2033629E (pt) Composição farmacêutica sólida que compreende valsartan
PT1813402E (pt) Placa de fibras de madeira com proteção antifúngica para a construção de telhados e de paredes, e processo para a sua produção
PL1869392T3 (pl) Substancja detonująca szczególnie niewrażliwa oraz sposób jej wytwarzania
HK1128001A (en) Solid dosage forms of valsartan, amlodipine and hydrochlorothiazide and method of making the same
HK1117393A (en) Solid dosage forms of valsartan and amlodipine and method of making the same
HK1127282B (en) Solid dosage form of olmesartan medoxomil and amlodipine
TWI436790B (en) Oral pharmaceutical composition containing valsartan and amlodipine or valsartan, hydrochlorothiazide and amlodipine
PL388087A1 (pl) Forma stała medoksomilu olmesartanu i amlodypiny
GB0603605D0 (en) Process, compounds and their uses